ABSTRACT
Even though the COVID-19 epidemic caused many problems for global supply chains, it also created opportunities that helped get people interested in cleaner production, sustainability, and business practices that are good for the environment again. This study seeks to examine the pandemic's opportunities for enhancing green supply chain management (GSC-management) and Sustainable environmental-performance by exploring the link between the uncertainty-anxiety of the pandemic, GSC-management, and Sustainable environmental-performance and inspecting the moderating effect of novel technology adoption like big-data analysis capabilities (BDA) and blockchain technologies (BCT) on this relationship. A questionnaire of 517 managers of SMEs in Egypt was used to test and analyze hypotheses with the PLS-SEM method. The findings show that the uncertainty-anxiety of the pandemic improves GSC-management significantly. Also, BDA moderates the link between the uncertainty-anxiety of the pandemic and GSC-management. However, BCT does not moderate that direct link. Also, GSC-management positively affects a firm's sustainable environmental-performance. In addition, GSC-management significantly mediates the correlation between the uncertainty-anxiety of the pandemic and sustainable environmental-performance. The study's findings have massive implications for how SMEs will be managed during COVID-19. Also, it contributes to the theory by using the Social cognitive theory to show how the uncertainty-anxiety of the pandemic positively affects the GSC-management practices and how the dynamic capabilities theory explains the innovative technologies moderating effect of such relationship. • Uncertainty-anxiety of the pandemic improves GSC-management significantly. • BDA moderates uncertainty-anxiety and GSC-management relationship. • BDA does not moderate uncertainty-anxiety and GSC-management relationship. • GSC-management improves firms' sustainable environmental-performance. • GSC-management mediates uncertainty-anxiety and environmental-performance. [ FROM AUTHOR] Copyright of Journal of Cleaner Production is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
ABSTRACT
PTH-44 Figure 1Baseline data 2018 - 2019 (pre-p ndemic)[Figure omitted. See PDF]Abstract PTH-44 Figure 2Post PDSA 1, in progress April 2021 onwards[Figure omitted. See PDF]Abstract PTH-44 Figure 3Rates of endoscopy within 24 hours (%)[Figure omitted. See PDF]Abstract PTH-44 Figure 4Median length of stay (days)[Figure omitted. See PDF]Abstract PTH-44 Figure 5Mortality rates within 28 days of AUGIB (%)[Figure omitted. See PDF]ConclusionsUHMBT data and national data were comparable, with ample room to improve the Morecambe Bay AUGIB service and therefore outcomes for our patients in line with BSG recommendations. It is too early following PDSA 1 interventions to draw any meaningful conclusions from the data. However, a positive result appears achievable with improvements ongoing via further quarterly PDSA cycles throughout the remainder of the year. The authors look forward to presenting these results with the wider BSG community towards the end of 2021. The impact of the Covid-19 Pandemic will also be included in the final data and presentation.ReferencesSiau, Keith, et al. ‘British Society of Gastroenterology (BSG)-led multisociety consensus care bundle for the early clinical management of acute upper gastrointestinal bleeding.’ Frontline gastroenterology 11.4 (2020): 311-323 https://www.bsg.org.uk/wp-content/uploads/2019/11/flgastro-2019-101395.pdfMcPherson, S. J., et al. ‘Gastrointestinal haemorrhage: time to get control.’ London, UK: National Confidential Enquiry into Patient Outcome and Death (2015). https://www.ncepod.org.uk/2015report1/downloads/TimeToGetControlFullReport.pdf
ABSTRACT
In this paper daily confirmed cases of COVID -19 in different countries are modelled using different mathematical regression models. The mathematical curve fitting is used as a prediction tool to model both pervious and next upcoming Coronavirus waves. The used models cover virus spreading from 1/3/2020 to 10/4/2021. According to virus spreading, countries under study in this paper are categorized into three main categories. First category in which Coronavirus first wave takes about two year seasons (about 180 days) to make a complete virus cycle. Second category is countries with higher transmission rates with one year season (about 90 days) to make the first complete virus cycle. These countries take offline periods with low spreading rates. The third category is countries with the highest transmission rates and make complete virus cycles without offline periods. All categories are modelled with different mathematical fitting models. Finally, predictions of different upcoming scenarios for these countries are made.Funding Statement: The research is partially supported by P.R.I.N. 2019 and the RUDN University Program 5-100".Declaration of Interests: The authors have no competing interests.
Subject(s)
COVID-19ABSTRACT
Patients with severe COVID-19 have a hyperinflammatory immune response suggestive of macrophage activation. Bruton tyrosine kinase (BTK) regulates macrophage signaling and activation. Acalabrutinib, a selective BTK inhibitor, was administered off-label to 19 patients hospitalized with severe COVID-19 (11 on supplemental oxygen; 8 on mechanical ventilation), 18 of whom had increasing oxygen requirements at baseline. Over a 10-14 day treatment course, acalabrutinib improved oxygenation in a majority of patients, often within 1-3 days, and had no discernable toxicity. Measures of inflammation - C-reactive protein and IL-6 - normalized quickly in most patients, as did lymphopenia, in correlation with improved oxygenation. At the end of acalabrutinib treatment, 8/11 (72.7%) patients in the supplemental oxygen cohort had been discharged on room air, and 4/8 (50%) patients in the mechanical ventilation cohort had been successfully extubated, with 2/8 (25%) discharged on room air. Ex vivo analysis revealed significantly elevated BTK activity, as evidenced by autophosphorylation, and increased IL-6 production in blood monocytes from patients with severe COVID-19 compared with blood monocytes from healthy volunteers. These results suggest that targeting excessive host inflammation with a BTK inhibitor is a therapeutic strategy in severe COVID-19 and has led to a confirmatory international prospective randomized controlled clinical trial.